
Greencare Capital exits cannabis to focus on crypto and other sectors
To reflect the change, the company will now be called MaxRS Ventures plc.

To reflect the change, the company will now be called MaxRS Ventures plc.

Michael Sassano, CEO of Somai Pharmaceuticals reflects on Q3 2022.

AIM-listed cash shell company UK SPAC Plc has confirmed that the Financial Conduct Authority (FCA) has approved the prospectus of

BDSA has updated its cannabis market forecast.

Get up to date with the latest financial results from Jazz Pharma, Flora Growth, Khiron, MGC Pharma, CBD of Denver and Tilray.

Cannabis Europa explored the pros and cons of being a first mover in the nascent European industry.

Analysis from Prohibition Partners underscores how the UK’s inability to embrace the industry could come at a significant economic cost.

A new report from Fact.MR shows the market will grow at a CAGR of 31 per cent until 2032.

The CBX Stock Exchange is a B2B trading platform for raw cannabis materials.

The sales estimates were based on a survey of research firms covering the financial outlook of Aurora.

The cannabis producer’s stock shot up by 215 per cent on its first day of trading followed by a further 91 per cent increase yesterday.

Companies across the cannabis industry announce financial results for the first quarter of 2022, Cannabis Wealth rounds up the results

Apollon Formularies has announced the acquisition of four patents previously owned by AI Pharmaceuticals, covering a number of treatments for

The platform aims to be a premium destination for industry members to connect.

Akanda has now completed its acquisition of Holigen Limited from The Flowr Corporation.

A new cannabis-themed ETF has launched this 4/20 giving investors the opportunity to capitalise on the growing North American market.

The new Prohibition Partners report projects that sales of adult-use cannabis in Europe could reach €1.5bn by 2026.

Promising results reported from studies testing the efficacy of its lead compound.